Refractory Acute Myeloid Leukemia

Oncology·MeSH: Leukemia, Myeloid, Acute

Prevalence

6.0 / 100K

Incidence

4.3 / 100K/yr

18 drugs in development·14 companies·18 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
komzifti	Kura Oncology, Inc. (KURA)
Revuforj	Syndax Pharmaceuticals Inc (SNDX)

Phase 3(1)

Drug	Company
intrathecal chemotherapy	GH Research PLC (GHRS)

Phase 2(3)

Drug	Company
revumenib	GH Research PLC (GHRS)
rtx-240	Rubius Therapeutics, Inc. (RUBY)
UCART123v1.2	Cellectis S.A. (CLLS)

Phase 1(9)

Drug	Company
ACLX-002	Arcellx, Inc. (ACLX)
ADCLEC.syn1 CAR T cells	Merus N.V. (MRUS)
CB-012	Caribou Biosciences, Inc. (CRBU)
CD371-specific/YSNVz/I-18 CAR T cells	Merus N.V. (MRUS)
CLN-049	Cullinan Therapeutics, Inc. (CGEM)
nc525	NextCure, Inc. (NXTC)
sgr-2921	Schrodinger, Inc. (SDGR)
Tazemetostat	Merus N.V. (MRUS)
ZN-d5	Zentalis Pharmaceuticals, Inc. (ZNTL)

Preclinical(2)

Drug	Company
ACLX-004	Arcellx, Inc. (ACLX)
rasp-301	ACTAVIA LIFE SCIENCES, INC. (RASP)

Phase 1/Phase 2(1)

Drug	Company
nkx101	Nkarta, Inc. (NKTX)

BioSniper tracks 18 drugs in development for Refractory Acute Myeloid Leukemia across 14 companies.

There are 18 clinical trials targeting Refractory Acute Myeloid Leukemia tracked by BioSniper.

The estimated prevalence of Refractory Acute Myeloid Leukemia is approximately 6.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.